GLOBAL MARKETS AND TECHNOLOGIES FOR ADVANCED DRUG DELIVERY SYSTEMS



PHM006J January 2014

Shalini Shahani Dewan **Project Analyst**

ISBN: 1-56965-655-X



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHARTER 1 INTRODUCTION	
CHAPTER 1 INTRODUCTION	2
STUDY OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
INTENDED AUDIENCE	3
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	3
ABOUT THE AUTHOR	3
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH ONLINE SERVICES	4
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS, BY	
REGION, THROUGH 2018 (\$ MILLIONS)	7
SUMMARY FIGURE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS, BY REGION, 2011-2018 (\$ MILLIONS)	7
πεσιοιν, 2011 2010 (φ ιπεειοινό)	
CHAPTER 3 OVERVIEW	9
NEED FOR THE DOSAGE FORMS	9
TABLE 1 HISTORIC EVENTS IN DRUG DELIVERY	10
CLASSIFICATION OF DRUG DELIVERY ACCORDING TO TECHNOLOGY	10
SUSTAINED RELEASE DRUG DELIVERY	11
Oral Sustained Release Drug Delivery	11
Intramuscular (IM) Injections or Microsyringes	12
TABLE 2 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY	12
PRODRUGS	13
Subtypes of Prodrugs	14
TABLE 3 CLASSIFICATION OF PRODRUGS	14
Need for Prodrugs	15
TABLE 4 ADVANTAGES AND DISADVANTAGES OF PRODRUGS	15
IMPLANTS AND INTRAUTERINE DEVICES (IUDS)	16
Copper-based Devices	16
Hormonal-based Devices	16
Mechanism	17
TABLE 5 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS	17
TARGETED DRUG DELIVERY	18
Delivery Vehicles	18
Liposomes	18
TABLE 6 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES	19
Micelles and Dendrimers	19
Mechanisms of Drug Delivery	19
Advantages of Dendrimers	20
Biodegradable Particles	20
Artificial DNA Nanostructures	20

TOPIC	PAGE NO.
Monoclonal Antibodies	21
Applications	21
TABLE 7 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES	22
POLYMERIC DRUG DELIVERY	22
Applications of Polymers in Drug Delivery	22
TABLE 8 ADVANTAGES AND DISADVANTAGES OF POLYMERS	23
Pegylation	23
TABLE 9 ADVANTAGES AND DISADVANTAGES OF PEGYLATION	24
Future Perspectives	24
CLASSIFICATION OF DRUG DELIVERY BY ROUTE OF ADMINISTRATION	24
ORAL DRUG DELIVERY	24
TABLE 10 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY	25
INJECTABLE OR PARENTERAL DRUG DELIVERY	25
TABLE 11 ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY	25
PULMONARY DRUG DELIVERY	26
TABLE 12 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY	26
NASAL DRUG DELIVERY	27
TABLE 13 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY	27
ORAL MUCOSAL DRUG DELIVERY	27
TABLE 14 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG	21
DELIVERY	28
RECTAL DRUG DELIVERY	28
TABLE 15 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY	28
OCULAR DRUG DELIVERY	29
TABLE 16 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY	29
TRANSDERMAL DRUG DELIVERY	29
TABLE 17 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY	29
CHAPTER 4 REGULATORY ASPECTS	32
NEW PRODUCTS APPROVED IN 2009-2013	32
TABLE 18 FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013	32
FDA RECALLS AND SAFETY ALERTS	35
TABLE 19 PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013	35
TABLE 20 SAFETY ALERTS, 2009 TO JUNE 2013	37
CHAPTER 5 NEW DEVELOPMENTS	40
NEW PARTNERSHIPS, MERGERS AND ACQUISITION	40
TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013	41
NEW PRODUCTS	42
TABLE 22 NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013	43
PIPELINE PRODUCTS	44
TABLE 23 PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET	44
CHAPTER 6 GLOBAL MARKETS	46
MARKET BY TYPE	46
MARKET OVERVIEW	46
MARKET REVENUE	49

TOPIC	PAGE NO.
TABLE 24 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 (\$ MILLIONS)	49
FIGURE 1 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 (\$ MILLIONS)	49
MARKET SHARE	50
TABLE 25 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)	51
FIGURE 2 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)	51
MARKET BY REGION	51
SUSTAINED RELEASE DRUG DELIVERY SYSTEM	52
Market Overview	52
Market Revenue	53
TABLE 26 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	53
FIGURE 3 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	53
Market Share	54
TABLE 27 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2012 (%)	54
FIGURE 4 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2012 (%)	54
PRODRUGS	55
Market Overview	55
Market Revenue	56
TABLE 28 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	56
FIGURE 5 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	56
Market Share	57
TABLE 29 MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%)	57
FIGURE 6 MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%)	57
IMPLANTS AND IUDS	57
Market Overview	58
Market Revenue	58
TABLE 30 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 (\$ MILLIONS)	58
FIGURE 7 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 (\$ MILLIONS)	58
Market Share	59
TABLE 31 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)	59
FIGURE 8 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)	59
TRANSMUCOSAL DELIVERY SYSTEMS	60
Market Overview	61
Market Revenue	62
TABLE 32 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	63
FIGURE 9 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	63
Market Share	63
TABLE 33 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)	64

TOPIC	PAGE NO
FIGURE 10 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)	6
TARGETED DRUG DELIVERY	6
Market Overview	6
Market Revenue	6
TABLE 34 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	6
FIGURE 11 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	6
Market Share	6
TABLE 35 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)	6
FIGURE 12 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)	6
TRANSDERMAL DRUG DELIVERY SYSTEM	6
Market Overview	6
Market Revenue	6
TABLE 36 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	6
FIGURE 13 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011- 2018 (\$ MILLIONS)	6
Market Share	6
TABLE 37 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION, 2012 (\$ MILLIONS)	6
FIGURE 14 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	6
POLYMERIC DRUG DELIVERY	7
Market Overview	7
Market Revenue	7
TABLE 38 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	7
FIGURE 15 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	7
Market Share	7
TABLE 39 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)	7
FIGURE 16 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)	7
MARKET BY END USERS	7
MARKET OVERVIEW	7
MARKET REVENUE	-
TABLE 40 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 (\$ MILLIONS)	-
FIGURE 17 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011–2018 (\$ MILLIONS)	-
MARKET SHARE	7
TABLE 41 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)	8
FIGURE 18 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)	8
HAPTER 7 MARKET ANALYSIS FOR ADVANCED DRUG DELIVERY SYSTEMS BY ECHNOLOGY	

TOPIC	PAGE NO.
TABLE 42 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY, THROUGH 2018 (\$ MILLIONS)	82
FIGURE 19 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY, 2011-2018 (\$ MILLIONS)	82
MARKET BY TYPE	83
SUSTAINED RELEASE	84
Market Overview	84
Market Revenue	85
TABLE 43 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 (\$ MILLIONS)	86
FIGURE 20 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 (\$ MILLIONS)	86
PRODRUGS	86
Market Overview	87
Market Revenue	87
TABLE 44 GLOBAL REVENUE OF PRODRUGS, THROUGH 2018 (\$ MILLIONS)	87
FIGURE 21 GLOBAL REVENUE OF PRODRUGS, 2011-2018 (\$ MILLIONS)	88
IMPLANTS AND IUDS	88
Market Overview	88
Market Revenue	89
TABLE 45 GLOBAL REVENUE OF IMPLANTS AND IUDS*, THROUGH 2018 (\$ MILLIONS)	89
FIGURE 22 GLOBAL REVENUE OF IMPLANTS AND IUDS*, 2011-2018 (\$ MILLIONS)	89
TARGETED DRUG DELIVERY	90
Market Overview	90
Liposomes	90
Nanoparticles	90
Monoclonal Antibodies	91
Market Revenue	91
TABLE 46 GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	92
FIGURE 23 GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	92
POLYMERIC DRUG DELIVERY	93
Market Overview	93
Market Revenue	94
TABLE 47 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	94
FIGURE 24 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	94
MARKET BY REGION	95
MARKET OVERVIEW	95
MARKET REVENUES	96
Oral Sustained Release Delivery	96
TABLE 48 GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	97
FIGURE 25 GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	97
Injectable Sustained Release Delivery	98

TOPIC	PAGE NO.
TABLE 49 GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	98
FIGURE 26 GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	98
Topical Sustained Release Delivery	99
TABLE 50 GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	99
FIGURE 27 GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	99
Prodrugs	100
TABLE 51 GLOBAL REVENUE OF PRODRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)	100
FIGURE 28 GLOBAL REVENUE OF PRODRUGS BY REGION, 2011-2018 (\$ MILLIONS)	100
Implants and IUDs	101
TABLE 52 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 (\$ MILLIONS)	102
FIGURE 29 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 (\$ MILLIONS)	102
Targeted Drug Delivery	102
TABLE 53 GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	103
FIGURE 30 GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	103
TABLE 54 GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	104
FIGURE 31 GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	104
TABLE 55 GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	105
FIGURE 32 GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	105
Polymeric Drug Delivery	105
Polymers	105
TABLE 56 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	106
FIGURE 33 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	106
Pegylated Drugs	106
TABLE 57 GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	107
FIGURE 34 GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	107
INDUSTRY STRUCTURE	108
SUSTAINED RELEASE	108
Market Leaders	108
TABLE 58 MAJOR MANUFACTURERS IN SUSTAINED RELEASE DRUG DELIVERY, 2012	108
Market Share	108
TABLE 59 MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG DELIVERY, 2012 (%)	109
FIGURE 35 MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG DELIVERY, 2012 (%)	109

TOPIC	PAGE NO.
PRODRUGS	110
Market Leaders	110
TABLE 60 MAJOR MANUFACTURERS OF PRODRUGS, 2012	110
Market Share	110
TABLE 61 MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%)	110
FIGURE 36 MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%)	111
IMPLANTS AND IUDS	111
Market Leaders	111
TABLE 62 MAJOR MANUFACTURERS OF IMPLANTS AND IUDS, 2012	111
Market Share	112
TABLE 63 MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012 (%)	112
FIGURE 37 MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012 (%)	112
TARGETED DELIVERY	113
Market Leaders	113
TABLE 64 MAJOR MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012	113
Market Share	114
TABLE 65 MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 (%)	114
FIGURE 38 MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 (%)	114
POLYMERIC DRUG DELIVERY	115
Market Leaders	115
TABLE 66 MAJOR MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012	115
Market Share	115
TABLE 67 MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 (%)	115
FIGURE 39 MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 (%)	116
CHAPTER 8 MARKET ANALYSIS FOR ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION	118
TABLE 68 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION, THROUGH 2018 (\$ MILLIONS)	119
FIGURE 40 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION, 2011–2018 (\$ MILLIONS)	119
MARKET BY TYPE	120
ORAL, TOPICAL AND INJECTABLE DRUG DELIVERIES	120
Market Overview	121
Market Revenue	122
TABLE 69 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY TYPE, THROUGH 2018 (\$ MILLIONS)	122
FIGURE 41 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY TYPE, 2011-2018 (\$ MILLIONS)	123
TRANSMUCOSAL DELIVERY SYSTEMS	123
Market Overview	124
Market Revenue	126
TABLE 70 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE, THROUGH 2018 (\$ MILLIONS)	127

TOPIC	PAGE NO.
FIGURE 42 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE, 2011-2018 (\$ MILLIONS)	127
TRANSDERMAL DRUG DELIVERY SYSTEM	128
Market Overview	129
Market Revenue	129
TABLE 71 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	129
FIGURE 43 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	129
MARKET BY REGION	130
MARKET OVERVIEW	130
MARKET REVENUE	131
Oral, Topical, Injectables	132
TABLE 72 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	132
FIGURE 44 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	132
Transmucosal Drug Delivery	133
TABLE 73 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	133
FIGURE 45 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	133
Transdermal Drug Delivery	133
TABLE 74 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	134
FIGURE 46 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	135
INDUSTRY STRUCTURE	135
ORAL, INJECTABLE AND TOPICAL DRUG DELIVERY	135
Market Leaders	135
TABLE 75 MAJOR MANUFACTURERS IN ORAL, INJECTABLE AND TOPICAL DRUG DELIVERY, 2012	135
Market Share of Oral Drug Delivery	136
TABLE 76 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012 (%)	136
FIGURE 47 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012 (%)	137
Market Share of Injectable Drug Delivery	137
TABLE 77 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS, 2012 (%)	137
FIGURE 48 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS, 2012 (%)	138
Market Share of Topical Drug Delivery	138
TABLE 78 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS, 2012 (%)	138
FIGURE 49 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS, 2012 (%)	139
TRANSMUCOSAL DRUG DELIVERY	139
Market Leaders	139
TABLE 79 MAJOR MANUFACTURERS IN TRANSMUCOSAL DRUG DELIVERY	140

TOPIC	PAGE NO.
Market Share of Nasal Drug Delivery	141
TABLE 80 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL DRUG DELIVERY, 2012 (%)	141
FIGURE 50 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL DRUG DELIVERY, 2012 (%)	141
Market Share of Oral Mucosal/Buccal Drug Delivery	142
TABLE 81 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY, 2012 (%)	142
FIGURE 51 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY, 2012 (%)	142
Market Share of Rectal Drug Delivery	142
TABLE 82 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY, 2012 (%)	143
FIGURE 52 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY, 2012 (%)	143
Market Share of Ocular Drug Delivery	143
TABLE 83 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY, 2012 (%)	145
FIGURE 53 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY, 2012 (%)	145
Market Share of Vaginal Drug Delivery	145
TABLE 84 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY, 2012 (%)	146
FIGURE 54 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY, 2012 (%)	146
TRANSDERMAL DRUG DELIVERY	147
Market Leaders	147
TABLE 85 MAJOR MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012	147
Market Share	147
TABLE 86 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 (%)	147
FIGURE 55 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 (%)	148
CHAPTER 9 MARKET BY END USERS	150
TABLE 87 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 (\$ MILLIONS)	151
FIGURE 56 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011—2018 (\$ MILLIONS)	151
CARDIOVASCULAR DISEASES	152
MARKET REVENUE	153
TABLE 88 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	153
FIGURE 57 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, 2011–2018 (\$ MILLIONS)	153
MARKET SHARE	154
TABLE 89 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	154
FIGURE 58 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	154
ONCOLOGY	155

TOPIC	PAGE NO.
MARKET REVENUE	156
TABLE 90 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	156
FIGURE 59 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	156
MARKET SHARE	157
TABLE 91 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	157
FIGURE 60 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	157
GASTROINTESTINAL SYSTEMS	157
MARKET REVENUE	158
TABLE 92 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	158
FIGURE 61 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	158
MARKET SHARE	159
TABLE 93 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2012 (%)	159
FIGURE 62 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2012 (%)	159
UROLOGY	160
MARKET REVENUE	161
TABLE 94 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	161
FIGURE 63 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	161
MARKET SHARE	161
TABLE 95 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	162
FIGURE 64 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	162
DIABETES	162
MARKET REVENUE	163
TABLE 96 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, THROUGH 2018 (\$ MILLIONS)	163
FIGURE 65 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, 2011-2018 (\$ MILLIONS)	163
MARKET SHARE	164
TABLE 97 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION, 2012 (%)	164
FIGURE 66 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION, 2012 (%)	164
CENTRAL NERVOUS SYSTEM	165
MARKET REVENUE	165
TABLE 98 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	166
FIGURE 67 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	166
MARKET SHARE	166

TOPIC	PAGE NO.
TABLE 99 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	167
FIGURE 68 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	167
RESPIRATORY DRUG DELIVERY SYSTEMS	167
MARKET REVENUE	168
TABLE 100 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	168
FIGURE 69 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	168
MARKET SHARE	169
TABLE 101 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	169
FIGURE 70 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	169
INFLAMMATORY DISEASES AND ALLERGIES	169
MARKET REVENUE	170
TABLE 102 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES, THROUGH 2018 (\$ MILLIONS)	170
FIGURE 71 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES, 2011–2018 (\$ MILLIONS)	170
MARKET SHARE	171
TABLE 103 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2012 (%)	171
FIGURE 72 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2012 (%)	171
OPHTHALMOLOGY	172
MARKET REVENUE	173
TABLE 104 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH 2018 (\$ MILLIONS)	173
FIGURE 73 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, 2011–2018 (\$ MILLIONS)	173
MARKET SHARE	174
TABLE 105 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY REGION, 2012 (%)	174
FIGURE 74 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY REGION, 2012 (%)	174
VIRAL AND BACTERIAL DISEASES	175
MARKET REVENUE	175
TABLE 106 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES, THROUGH 2018 (\$ MILLIONS)	175
FIGURE 75 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES, 2011–2018 (\$ MILLIONS)	176
MARKET SHARE	176
TABLE 107 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES BY REGION, 2012 (%)	176
FIGURE 76 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES BY REGION, 2012 (%)	176
HORMONE REPLACEMENT THERAPY AND GYNECOLOGY	177
MARKET REVENUE	178

TOPIC	PAGE NO.
TABLE 108 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2018 (\$ MILLIONS)	178
FIGURE 77 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, 2011-2018 (\$ MILLIONS)	178
MARKET SHARE	179
TABLE 109 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%)	179
FIGURE 78 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%)	179
OTHERS	180
MARKET REVENUE	181
TABLE 110 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES, THROUGH 2018 (\$ MILLIONS)	181
FIGURE 79 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2011-2018 (\$ MILLIONS)	181
MARKET SHARE	182
TABLE 111 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012 (%)	182
FIGURE 80 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012 (%)	182
MARKET SHARE OF APPLICATIONS	182
TABLE 112 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012 (%)	182
FIGURE 81 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012 (%)	183
CHAPTER 10 PATENT ANALYSIS	185
PATENTS BY YEAR	185
TABLE 113 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013	185
FIGURE 82 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013	185
PATENTS BY CATEGORY	186
TABLE 114 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013	186
FIGURE 83 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013	187
PATENTS BY TYPE	187
TABLE 115 NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013	187
PATENTS BY COMPANY	188
TABLE 116 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013	188
PATENTS BY COUNTRY	190
TABLE 117 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013	190
PATENTS BY ASSIGNEE	191
TABLE 118 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013	191
FIGURE 84 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013	191
CHAPTER 11 CURRENT SITUATION	194
CHAPTER 12 COMPANY PROFILES	198
3M COMPANY	198
ABBOTT LABORATORIES	198
ACTAVIS INC.	199

TOPIC	PAGE NO
AKELA PHARMA INC.	199
AKORN, INC.	200
ALCON INC.	200
ALEXION PHARMACEUTICALS, INC.	203
ALKERMES	203
ALLERGAN INC.	203
AMGEN INC.	202
A.P. PHARMA	203
APTALIS PHARMA INC.	203
ASTELLAS PHARMA INC.	204
ASTRAZENECA PLC	204
ATON PHARMA	20
BAUSCH & LOMB	20
BAXTER INTERNATIONAL INC.	20
BAYER HEALTHCARE PHARMACEUTICALS	200
BIOGEN IDEC	20
BIOSANTE PHARMACEUTICALS, INC.	20
BOEHRINGER INGELHEIM	20
BOSTON SCIENTIFIC	20
BRISTOL MYERS SQUIBB	20
CELGENE CORPORATION	20
CEPHALON, INC.	20
COLUMBIA LABORATORIES, INC.	21
EISAI CO., LTD	21
ELAN DRUG TECHNOLOGIES	21
ENZON PHARMACEUTICALS	21
GENENTECH INC.	21
GENEREX BIOTECHNOLOGY CORPORATION	21
GENZYME CORPORATION	21
GILEAD SCIENCES, INC.	21
GLAXOSMITHKLINE PLC	21
HISAMITSU PHARMACEUTICAL CO., INC.	21
IMCLONE SYSTEMS INC.	21
JANSSEN BIOTECH, INC.	21
JOHNSON & JOHNSON	21
KEMPHARM, INC.	21
K.V. PHARMACEUTICAL CO.	21
LAVIPHARM CORPORATION	21
MANNKIND CORPORATION	21
MERCK & CO.	21
MYLAN LABORATORIES INC.	21
NEKTAR THERAPEUTICS	22
NEUROGESX INC.	22
NEWGEN BIOPHARMA	22
NOVARTIS AG	22
NOVAVAX, INC.	22
NOVEN PHARMACEUTICALS, INC.	22

TOPIC	PAGE NO.
NYCOMED US INC.	223
OSI PHARMACEUTICALS, INC.	223
PAR PHARMACEUTICAL COMPANIES, INC.	224
PDL BIOPHARMA, INC.	224
PFIZER INC.	225
QLT INC.	225
ROCHE HOLDING AG	226
SANOFI SA	226
TEVA PHARMACEUTICAL INDUSTRIES LTD.	227
THERAJECT, INC.	228
UMEWORLD LTD.	228
VALEANT PHARMACEUTICALS INTERNATIONAL, INC.	229
XEL PHARMACEUTICALS, INC.	229
CHAPTER 13 APPENDIX I	231

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS, BY REGION, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 HISTORIC EVENTS IN DRUG DELIVERY	10
TABLE 2 ADVANTAGES AND DISADVANTAGES OF SUSTAINED RELEASE DRUG DELIVERY	12
TABLE 3 CLASSIFICATION OF PRODRUGS	14
TABLE 4 ADVANTAGES AND DISADVANTAGES OF PRODRUGS	15
TABLE 5 ADVANTAGES AND DISADVANTAGES OF IMPLANTS AND IUDS	17
TABLE 6 ADVANTAGES AND DISADVANTAGES OF LIPOSOMES	19
TABLE 7 ADVANTAGES AND DISADVANTAGES OF MONOCLONAL ANTIBODIES	22
TABLE 8 ADVANTAGES AND DISADVANTAGES OF POLYMERS	23
TABLE 9 ADVANTAGES AND DISADVANTAGES OF PEGYLATION	24
TABLE 10 ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY	25
TABLE 11 ADVANTAGES AND DISADVANTAGES OF PARENTRAL DRUG DELIVERY	25
TABLE 12 ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY	26
TABLE 13 ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY	27
TABLE 14 ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DRUG DELIVERY	28
TABLE 15 ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY	28
TABLE 16 ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY	29
TABLE 17 ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY	29
TABLE 18 FDA-APPROVED NEW PRODUCTS, 2009-JULY 2013	32
TABLE 19 PRODUCT RECALLS: DRUG DELIVERY, 2009-JUNE 2013	35
TABLE 20 SAFETY ALERTS, 2009 TO JUNE 2013	37
TABLE 21 NEW PARTNERSHIPS, MERGERS AND ACQUISITIONS, 2009-JUNE 2013	41
TABLE 22 NEW INNOVATIONS IN DRUG DELIVERY, 2009-JUNE 2013	43
TABLE 23 PIPELINE PRODUCTS FOR DRUG DELIVERY MARKET	44
TABLE 24 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 (\$ MILLIONS)	49
TABLE 25 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)	51
TABLE 26 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	53
TABLE 27 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2012 (%)	54
TABLE 28 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	56
TABLE 29 MARKET SHARE OF PRODRUGS DRUG DELIVERY, BY REGION, 2012 (%)	57
TABLE 30 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 (\$ MILLIONS)	58
TABLE 31 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)	59
TABLE 32 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	63
TABLE 33 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)	64
TABLE 34 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	66
TABLE 35 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)	67
TABLE 36 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	68
TABLE 37 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEM BY REGION, 2012 (\$ MILLIONS)	69

TABLE HEADING	PAGE NO.
TABLE 38 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	71
TABLE 39 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)	72
TABLE 40 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 (\$ MILLIONS)	78
TABLE 41 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)	80
TABLE 42 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY, THROUGH 2018 (\$ MILLIONS)	82
TABLE 43 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY TYPE, THROUGH 2018 (\$ MILLIONS)	86
TABLE 44 GLOBAL REVENUE OF PRODRUGS, THROUGH 2018 (\$ MILLIONS)	87
TABLE 45 GLOBAL REVENUE OF IMPLANTS AND IUDS*, THROUGH 2018 (\$ MILLIONS)	89
TABLE 46 GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	92
TABLE 47 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	94
TABLE 48 GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	97
TABLE 49 GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	98
TABLE 50 GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	99
TABLE 51 GLOBAL REVENUE OF PRODRUGS BY REGION, THROUGH 2018 (\$ MILLIONS)	100
TABLE 52 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, THROUGH 2018 (\$ MILLIONS)	102
TABLE 53 GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	103
TABLE 54 GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	104
TABLE 55 GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	105
TABLE 56 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	106
TABLE 57 GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	107
TABLE 58 MAJOR MANUFACTURERS IN SUSTAINED RELEASE DRUG DELIVERY, 2012	108
TABLE 59 MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG DELIVERY, 2012 (%)	109
TABLE 60 MAJOR MANUFACTURERS OF PRODRUGS, 2012	110
TABLE 61 MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%)	110
TABLE 62 MAJOR MANUFACTURERS OF IMPLANTS AND IUDS, 2012	111
TABLE 63 MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012 (%)	112
TABLE 64 MAJOR MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012	113
TABLE 65 MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 (%)	114
TABLE 66 MAJOR MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012	115
TABLE 67 MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 (%)	115

TABLE HEADING	PAGE NO.
TABLE 68 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION, THROUGH 2018 (\$ MILLIONS)	119
TABLE 69 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY TYPE, THROUGH 2018 (\$ MILLIONS)	122
TABLE 70 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE, THROUGH 2018 (\$ MILLIONS)	127
TABLE 71 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	129
TABLE 72 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	132
TABLE 73 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	133
TABLE 74 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, THROUGH 2018 (\$ MILLIONS)	134
TABLE 75 MAJOR MANUFACTURERS IN ORAL, INJECTABLE AND TOPICAL DRUG DELIVERY, 2012	135
TABLE 76 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012 (%)	136
TABLE 77 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS, 2012 (%)	137
TABLE 78 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS, 2012 (%)	138
TABLE 79 MAJOR MANUFACTURERS IN TRANSMUCOSAL DRUG DELIVERY	140
TABLE 80 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL DRUG DELIVERY, 2012 (%)	141
TABLE 81 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY, 2012 (%)	142
TABLE 82 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY, 2012 (%)	143
TABLE 83 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY, 2012 (%)	145
TABLE 84 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY, 2012 (%)	146
TABLE 85 MAJOR MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012	147
TABLE 86 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 (%)	147
TABLE 87 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, THROUGH 2018 (\$ MILLIONS)	151
TABLE 88 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	153
TABLE 89 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	154
TABLE 90 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	156
TABLE 91 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	157
TABLE 92 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	158
TABLE 93 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2012 (%)	159
TABLE 94 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	161

TABLE HEADING	PAGE NO.
TABLE 95 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	162
TABLE 96 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, THROUGH 2018 (\$ MILLIONS)	163
TABLE 97 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION, 2012 (%)	164
TABLE 98 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	166
TABLE 99 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	167
TABLE 100 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, THROUGH 2018 (\$ MILLIONS)	168
TABLE 101 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	169
TABLE 102 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES, THROUGH 2018 (\$ MILLIONS)	170
TABLE 103 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2012 (%)	171
TABLE 104 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, THROUGH 2018 (\$ MILLIONS)	173
TABLE 105 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY REGION, 2012 (%)	174
TABLE 106 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES, THROUGH 2018 (\$ MILLIONS)	175
TABLE 107 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES BY REGION, 2012 (%)	176
TABLE 108 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, THROUGH 2018 (\$ MILLIONS)	178
TABLE 109 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%)	179
TABLE 110 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES, THROUGH 2018 (\$ MILLIONS)	181
TABLE 111 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012 (%)	182
TABLE 112 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012 (%)	182
TABLE 113 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013	185
TABLE 114 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013	186
TABLE 115 NUMBER OF U.S. PATENTS BY TYPE, JANUARY 2009-JULY 2013	187
TABLE 116 NUMBER OF U.S. PATENTS BY COMPANY, JANUARY 2009-JULY 2013	188
TABLE 117 NUMBER OF U.S. PATENTS BY COUNTRY, JANUARY 2009-JULY 2013	190
TABLE 118 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013	191

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS, BY REGION, 2011-2018 (\$ MILLIONS)	7
FIGURE 1 GLOBAL REVENUE OF DRUG DELIVERY SYSTEMS BY TYPE, 2011–2018 (\$ MILLIONS)	49
FIGURE 2 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY TYPE, 2012 (%)	51
FIGURE 3 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	53
FIGURE 4 MARKET SHARE OF SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2012 (%)	54
FIGURE 5 GLOBAL REVENUE OF PRODRUGS DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	56
FIGURE 6 MARKET SHARE OF PRODRUGS DRUG DELIVERY BY REGION, 2012 (%)	57
FIGURE 7 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 (\$ MILLIONS)	58
FIGURE 8 MARKET SHARE OF IMPLANTS AND IUDS BY REGION, 2012 (%)	59
FIGURE 9 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	63
FIGURE 10 MARKET SHARE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2012 (%)	64
FIGURE 11 GLOBAL REVENUE OF TARGETED DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	66
FIGURE 12 MARKET SHARE OF TARGETED DRUG DELIVERY BY REGION, 2012 (%)	67
FIGURE 13 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	68
FIGURE 14 MARKET SHARE OF TRANSDERMAL DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	69
FIGURE 15 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	71
FIGURE 16 MARKET SHARE OF POLYMERIC DRUG DELIVERY BY REGION, 2012 (%)	72
FIGURE 17 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011–2018 (\$ MILLIONS)	78
FIGURE 18 MARKET SHARE OF DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2012 (%)	80
FIGURE 19 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY TECHNOLOGY, 2011-2018 (\$ MILLIONS)	82
FIGURE 20 GLOBAL REVENUE OF SUSTAINED RELEASE DRUG DELIVERY SYSTEMS BY TYPE, 2011-2018 (\$ MILLIONS)	86
FIGURE 21 GLOBAL REVENUE OF PRODRUGS, 2011–2018 (\$ MILLIONS)	88
FIGURE 22 GLOBAL REVENUE OF IMPLANTS AND IUDS*, 2011–2018 (\$ MILLIONS)	89
FIGURE 23 GLOBAL REVENUE OF TARGETED DRUG DELIVERY SYSTEMS, 2011–2018 (\$ MILLIONS)	92
FIGURE 24 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	94
FIGURE 25 GLOBAL REVENUE OF ORAL SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	97
FIGURE 26 GLOBAL REVENUE OF INJECTABLE SUSTAINED RELEASE DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	98
FIGURE 27 GLOBAL REVENUE OF TOPICAL SUSTAINED RELEASE DRUG DELIVERY BY	99
REGION, 2011-2018 (\$ MILLIONS)	

FIGURE TITLE	PAGE NO.
FIGURE 29 GLOBAL REVENUE OF IMPLANTS AND IUDS BY REGION, 2011-2018 (\$ MILLIONS)	102
FIGURE 30 GLOBAL REVENUE OF LIPOSOMES DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	103
FIGURE 31 GLOBAL REVENUE OF NANOPARTICLES DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	104
FIGURE 32 GLOBAL REVENUE OF MONOCLONAL ANTIBODIES DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	105
FIGURE 33 GLOBAL REVENUE OF POLYMERIC DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	106
FIGURE 34 GLOBAL REVENUE OF PEGYLATED DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	107
FIGURE 35 MARKET SHARE OF THE MANUFACTURERS IN SUSTAINED DRUG DELIVERY, 2012 (%)	109
FIGURE 36 MARKET SHARE OF THE MANUFACTURERS IN PRODRUGS, 2012 (%)	111
FIGURE 37 MARKET SHARE OF THE MANUFACTURERS OF IMPLANTS AND IUDS, 2012 (%)	112
FIGURE 38 MARKET SHARE OF THE MANUFACTURERS IN TARGETED DRUG DELIVERY, 2012 (%)	114
FIGURE 39 MARKET SHARE OF THE MANUFACTURERS IN POLYMERIC DRUG DELIVERY, 2012 (%)	116
FIGURE 40 GLOBAL REVENUE OF ADVANCED DRUG DELIVERY SYSTEMS BY ROUTE OF ADMINISTRATION, 2011–2018 (\$ MILLIONS)	119
FIGURE 41 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY TYPE, 2011–2018 (\$ MILLIONS)	123
FIGURE 42 GLOBAL REVENUE OF TRANSMUCOSAL DELIVERY SYSTEMS BY TYPE, 2011–2018 (\$ MILLIONS)	127
FIGURE 43 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY SYSTEMS, 2011–2018 (\$ MILLIONS)	129
FIGURE 44 GLOBAL REVENUE OF ORAL, TOPICAL AND INJECTABLE DRUG DELIVERY BY REGION, 2011-2018 (\$ MILLIONS)	132
FIGURE 45 GLOBAL REVENUE OF TRANSMUCOSAL DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	133
FIGURE 46 GLOBAL REVENUE OF TRANSDERMAL DRUG DELIVERY BY REGION, 2011–2018 (\$ MILLIONS)	135
FIGURE 47 MARKET SHARE FOR MANUFACTURERS OF ORAL DOSAGE FORMS, 2012 (%)	137
FIGURE 48 MARKET SHARE FOR MANUFACTURERS OF INJECTABLE DOSAGE FORMS, 2012 (%)	138
FIGURE 49 MARKET SHARE FOR MANUFACTURERS OF TOPICAL DOSAGE FORMS, 2012 (%)	139
FIGURE 50 MARKET SHARE OF THE MANUFACTURERS IN PULMONARY AND NASAL DRUG DELIVERY, 2012 (%)	141
FIGURE 51 MARKET SHARE OF THE MANUFACTURERS IN BUCCAL DRUG DELIVERY, 2012 (%)	142
FIGURE 52 MARKET SHARE OF THE MANUFACTURERS IN RECTAL DRUG DELIVERY, 2012 (%)	143
FIGURE 53 MARKET SHARE OF THE MANUFACTURERS IN OCULAR DRUG DELIVERY, 2012 (%)	145
FIGURE 54 MARKET SHARE OF THE MANUFACTURERS IN VAGINAL DRUG DELIVERY, 2012 (%)	146

FIGURE TITLE	PAGE NO.
FIGURE 55 MARKET SHARE OF THE MANUFACTURERS IN TRANSDERMAL DRUG DELIVERY, 2012 (%)	148
FIGURE 56 GLOBAL MARKET FOR DRUG DELIVERY DOSAGE FORMS BY APPLICATIONS, 2011—2018 (\$ MILLIONS)	151
FIGURE 57 GLOBAL MARKET FOR CARDIOVASCULAR DRUG DELIVERY SYSTEMS, 2011–2018 (\$ MILLIONS)	153
FIGURE 58 MARKET SHARE OF CARDIOVASCULAR DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	154
FIGURE 59 GLOBAL MARKET FOR ONCOLOGY DRUG DELIVERY SYSTEMS, 2011–2018 (\$ MILLIONS)	156
FIGURE 60 MARKET SHARE OF ONCOLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	157
FIGURE 61 GLOBAL MARKET FOR GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2011–2018 (\$ MILLIONS)	158
FIGURE 62 GLOBAL SHARE OF REGIONS IN GASTROINTESTINAL DRUG DELIVERY SYSTEMS, 2012 (%)	159
FIGURE 63 GLOBAL MARKET FOR UROLOGY DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	161
FIGURE 64 MARKET SHARE OF UROLOGY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	162
FIGURE 65 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN DIABETES, 2011–2018 (\$ MILLIONS)	163
FIGURE 66 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN DIABETES BY REGION, 2012 (%)	164
FIGURE 67 GLOBAL MARKET FOR CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS, 2011–2018 (\$ MILLIONS)	166
FIGURE 68 MARKET SHARE OF CENTRAL NERVOUS SYSTEM DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	167
FIGURE 69 GLOBAL MARKET FOR RESPIRATORY DRUG DELIVERY SYSTEMS, 2011-2018 (\$ MILLIONS)	168
FIGURE 70 MARKET SHARE IN RESPIRATORY DRUG DELIVERY SYSTEMS BY REGION, 2012 (%)	169
FIGURE 71 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES, 2011–2018 (\$ MILLIONS)	170
FIGURE 72 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR INFLAMMATORY DISEASES AND ALLERGIES BY REGION, 2012 (%)	171
FIGURE 73 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY, 2011-2018 (\$ MILLIONS)	173
FIGURE 74 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OPHTHALMOLOGY BY REGION, 2012 (%)	174
FIGURE 75 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES, 2011-2018 (\$ MILLIONS)	176
FIGURE 76 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR VIRAL AND BACTERIAL DISEASES BY REGION, 2012 (%)	176
FIGURE 77 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY, 2011–2018 (\$ MILLIONS)	178
FIGURE 78 MARKET SHARE OF DRUG DELIVERY SYSTEMS FOR HORMONE REPLACEMENT THERAPY AND GYNECOLOGY BY REGION, 2012 (%)	179
FIGURE 79 GLOBAL MARKET FOR DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2011-2018 (\$ MILLIONS)	181
FIGURE 80 MARKET SHARE OF DRUG DELIVERY SYSTEMS IN OTHER DISEASES, 2012 (%)	182

FIGURE TITLE	PAGE NO.
FIGURE 81 MARKET SHARE OF DRUG DELIVERY SYSTEMS BY APPLICATIONS, 2012 (%)	183
FIGURE 82 NUMBER OF U.S. PATENTS BY YEAR, JANUARY 2009-JULY 2013	185
FIGURE 83 NUMBER OF U.S. PATENTS BY CATEGORY, JANUARY 2009-JULY 2013	187
FIGURE 84 NUMBER OF U.S. PATENTS BY ASSIGNEE, JANUARY 2009-JULY 2013	191